A Randomized, Placebo-Controlled Trial of Citalopram for the Treatment of Major Depression in Children and Adolescents
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Open-label trials with the selective serotonin reuptake inhibitor citalopram suggest that this agent is effective and safe for the treatment of depressive symptoms in children and adolescents. The current study investigated the efficacy and safety of citalopram compared with placebo in the treatment of pediatric patients with major depression. METHOD: An 8-week, randomized, double-blind, placebo-controlled study compared the safety and efficacy of citalopram with placebo in the treatment of children (ages 7-11) and adolescents (ages 12-17) with major depressive disorder. Diagnosis was established with the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version. Patients (N=174) were treated initially with placebo or 20 mg/day of citalopram, with an option to increase the dose to 40 mg/day at week 4 if clinically indicated. The primary outcome measure was score on the Children's Depression Rating Scale-Revised; the response criterion was defined as a score of < or =28. RESULTS: The overall mean citalopram dose was approximately 24 mg/day. Mean Children's Depression Rating Scale-Revised scores decreased significantly more from baseline in the citalopram treatment group than in the placebo treatment group, beginning at week 1 and continuing at every observation point to the end of the study (effect size=2.9). The difference in response rate at week 8 between placebo (24%) and citalopram (36%) also was statistically significant. Citalopram treatment was well tolerated. Rates of discontinuation due to adverse events were comparable in the placebo and citalopram groups (5.9% versus 5.6%, respectively). Rhinitis, nausea, and abdominal pain were the only adverse events to occur with a frequency exceeding 10% in either treatment group. CONCLUSIONS: In this population of children and adolescents, treatment with citalopram reduced depressive symptoms to a significantly greater extent than placebo treatment and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Emslie, G. J. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230069010 · Cited by 985
Depressed Adolescents Grown Up
Weissman, M. M. (1999) · JAMA · doi:10.1001/jama.281.18.1707 · Cited by 952
Epidemiology of Childhood Depressive Disorders: A Critical Review
FLEMING, J. E., & OFFORD, D. R. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00010 · Cited by 695
KELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641 · cited 1×
“treatment of depressed adolescents (13).”
Self-citationEMSLIE, G. J., HEILIGENSTEIN, J. H., WAGNER, K. D., HOOG, S. L., ERNEST, D. E., BROWN, E., NILSSON, M., & JACOBSON, J. G. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200210000-00010 · Cited by 581
Self-citationWagner, K. D. (2003) · JAMA · doi:10.1001/jama.290.8.1033 · Cited by 416
Self-citationA Depression Rating Scale for Children
Poznanski, E. O., Cook, S. C., & Carroll, B. J. (1979) · Pediatrics · doi:10.1542/peds.64.4.442 · Cited by 392
Depression in young people: Initial presentation and clinical course
McCAULEY, E., MYERS, K., MITCHELL, J., CALDERON, R., SCHLOREDT, K., & TREDER, R. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199307000-00003 · Cited by 343
Cited by
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
US Preventive Services Task Force (2010) · Pediatrics · doi:10.1542/peds.2009-2037 · Cited by 617
Childhood and Adolescent Depression: (552642011-001)
(2011) · PsycEXTRA Dataset · doi:10.1037/e552642011-001 · Cited by 447
Evidence-Based Psychosocial Treatments for Child and Adolescent Depression
David-Ferdon, C., & Kaslow, N. J. (2008) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374410701817865 · Cited by 390
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
“Factors suchas contactwith research staff may lead to large placebo response rates in pediatric DD(11) andmay explainmuchof the variability in pediatric antidepressant trials.(12) For adultswith DD, a genuine placebo effect has been demonstrated, as the combination of placebo andsupportive carehasbeenshowntobemorebene…”
Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management
Cheung, A. H., Zuckerbrot, R. A., Jensen, P. S., Ghalib, K., Laraque, D., Stein, R. E. K., & and the GLAD-PC Steering Group (2007) · Pediatrics · doi:10.1542/peds.2006-1395 · Cited by 336
Cheung, A. H., Zuckerbrot, R. A., Jensen, P. S., Laraque, D., Stein, R. E. K., GLAD-PC STEERING GROUP, Levitt, A., Birmaher, B., Campo, J., Clarke, G., et al. (2018) · Pediatrics · doi:10.1542/peds.2017-4082 · Cited by 299
“50, 52, 55, 59 61, 76, 77, 83, 84, 89 Not of the screens in these studies have specific psychometric validation data (eg, 2 depression questions on the GAPS).”
Newer generation antidepressants for depressive disorders in children and adolescents
Hetrick, S. E., McKenzie, J. E., Cox, G. R., Simmons, M. B., & Merry, S. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub3 · Cited by 291
KENNARD, B., SILVA, S., VITIELLO, B., CURRY, J., KRATOCHVIL, C., SIMONS, A., HUGHES, J., FEENY, N., WELLER, E., SWEENEY, M., et al. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000242228.75516.21 · Cited by 279
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256
“…12.7 49 82 79 Wagner et al. 2003 (25) Sertraline, 50–200 mg 2001 376 12.0 51 70 88 TADS Team 2004 (26)b Fluoxetine, 10–40 mg 2003 221e 14.6 54 74 86 Wagner et al. 2004 (21)b Citalopram, 20–40 mg 2001 178 12.0 53 77 81 Wagner et al. 2006 (27)b Escitalopram, 10–20 mg 2004 268 12.3 52 71 — Berard…”
InfluentialEmslie, G. J., Ventura, D., Korotzer, A., & Tourkodimitris, S. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181a2b304 · Cited by 210
Review of the efficacy and safety of antidepressants in youth depression
Cheung, A. H., Emslie, G. J., & Mayes, T. L. (2005) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2005.01467.x · Cited by 183
Safer, D. J., & Zito, J. M. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.159 · Cited by 182
“placebo (Geller et al. 2004; Wagner et al. 2002; Wagner et al. 2003; Wagner et al. 2004b).”
Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents
Hetrick, S. E., Merry, S. N., McKenzie, J., Sindahl, P., & Proctor, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub2 · Cited by 180
Treatment of depression in children and adolescents
Ryan, N. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67321-7 · Cited by 176
The Treatment for Adolescents With Depression Study (TADS)
MARCH, J., SILVA, S., & VITIELLO, B. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000237709.35637.c0 · Cited by 174
Venlafaxine ER for the Treatment of Pediatric Subjects With Depression
EMSLIE, G. J., FINDLING, R. L., YEUNG, P. P., KUNZ, N. R., & LI, Y. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31802f5f03 · Cited by 135
Self-citationWalkup, J. T. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091059 · Cited by 112
von Knorring, A.-L., Olsson, G. I., Thomsen, P. H., Lemming, O. M., & Hultén, A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000219051.40632.d5 · Cited by 111
“In conclusion, our study reflects the methodological difficulties with studies in adolescents and differs in outcome from another study.(4) Additional studies in adolescents are clearly needed to clarify both the therapeutic benefits and the recent concern regarding suicide-related behavior upon initiation of treatmen…”
BackgroundMethodResultInfluentialForman-Hoffman, V., McClure, E., McKeeman, J., Wood, C. T., Middleton, J. C., Skinner, A. C., Perrin, E. M., & Viswanathan, M. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2259 · Cited by 93
“The fourth trial tested citalopram versus placebo in a sample of children and adolescents aged 7 to 17 years (29) and was included in the 2009 review.”
BackgroundInfluentialThe pharmacological management of depression
Kupfer, D. J. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/dkupfer · Cited by 69
Joseph, M. F., Youngstrom, E. A., & Soares, J. C. (2008) · Future Neurology · doi:10.2217/14796708.4.1.87 · Cited by 68
The Relevance of Pharmacokinetic Studies in Designing Efficacy Trials in Juvenile Major Depression
Findling, R. L., McNamara, N. K., Stansbrey, R. J., Feeny, N. C., Young, C. M., Peric, F. V., & Youngstrom, E. A. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.131 · Cited by 64
Self-citationFindling, R. L., Robb, A., & Bose, A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0023 · Cited by 57
“In an 8-week, flexible-dose, placebo-controlled study of MDD in children and adolescents (7– 17 years of age), racemic citalopram 20–40 mg/day demonstrated significant improvement in depressive symptoms versus placebo within 1 week (Wagner et al. 2004).”
MethodSelf-citationAmitai, M., Kaffman, S., Kroizer, E., Lebow, M., Magen, I., Benaroya-Milshtein, N., Fennig, S., Weizman, A., Apter, A., & Chen, A. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.04.018 · Cited by 51
Relapse and Recurrence in Pediatric Depression
Kennard, B. D., Emslie, G. J., Mayes, T. L., & Hughes, J. L. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2006.05.003 · Cited by 50
Heiligenstein, J. H., Hoog, S. L., Wagner, K. D., Findling, R. L., Galil, N., Kaplan, S., Busner, J., Nilsson, M. E., Brown, E. B., & Jacobson, J. G. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.207 · Cited by 39
Self-citationRohden, A. I., Benchaya, M. C., Camargo, R. S., Moreira, T. D. C., Barros, H. M. T., & Ferigolo, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.017 · Cited by 35
Pharmacotherapy of Depressed Children and Adolescents: Current Issues and Potential Directions
Vasa, R. A., Carlino, A. R., & Pine, D. S. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.010 · Cited by 29
Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder
Blanco, C., Hoertel, N., Franco, S., Olfson, M., He, J.-P., López, S., González-Pinto, A., Limosin, F., & Merikangas, K. R. (2017) · Pediatrics · doi:10.1542/peds.2016-1701 · Cited by 29
Wells, K. B., Tang, L., Carlson, G. A., & Asarnow, J. R. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0074 · Cited by 28
“…by clinical trials include cognitive-behavior therapy, interpersonal psychotherapy, and certain selective serotonin reuptake inhibitors (SSRIs) (Emslie et al. 1997; Clarke et al. 1999; March et al. 2004; Mufson et al. 2004; Vitiello and Swedo 2004; Wagner et al. 2004a, 2004b; Brent et al. 2009).”
BackgroundDudley, M., Hadzi-Pavlovic, D., Andrews, D., & Perich, T. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802050538 · Cited by 15
A multisite psychotherapy and medication trial for depressed adolescents: background and benefits
Kratochvil, C. J., Simons, A., Vitiello, B., Walkup, J., Emslie, G., Rosenberg, D., & March, J. S. (2005) · Cognitive and Behavioral Practice · doi:10.1016/s1077-7229(05)80021-5 · Cited by 9
Frölich, J., Lehmkuhl, G., & Döpfner, M. (2010) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917.a000002 · Cited by 5
Metadata
- Authors
- Wagner, K. D., Robb, A. S., Findling, R. L., Jin, J., Gutierrez, M. M., & Heydorn, W. E.
- Venue
- American Journal of Psychiatry
- Published
- 2004-06
- Volume
- 161
- Issue
- 6
- Pages
- 1079-1083
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2169527820
- Cited by
- 308
- References
- 24
- FWCI
- 21.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.